CU24103B1 - Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos - Google Patents

Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos

Info

Publication number
CU24103B1
CU24103B1 CU2012000021A CU20120021A CU24103B1 CU 24103 B1 CU24103 B1 CU 24103B1 CU 2012000021 A CU2012000021 A CU 2012000021A CU 20120021 A CU20120021 A CU 20120021A CU 24103 B1 CU24103 B1 CU 24103B1
Authority
CU
Cuba
Prior art keywords
pharmaceutically acceptable
spirocycles
same
salts pharmaceutically
amido
Prior art date
Application number
CU2012000021A
Other languages
English (en)
Other versions
CU20120021A7 (es
Inventor
Lilian Alcaraz
Andrew Bailey
Nicholas Kindon
Original Assignee
Astrazeneca Ab
Pulmagen Therapeutics Synergy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41129405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24103(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Pulmagen Therapeutics Synergy filed Critical Astrazeneca Ab
Publication of CU20120021A7 publication Critical patent/CU20120021A7/es
Publication of CU24103B1 publication Critical patent/CU24103B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención refiere a un compuesto de fórmula: o una sal faramcéuticamente aceptable del mismo y a un compuesto de fórmula: Dichos compuestos de la presente invención y sus sales son útiles en el tratamiento de enfermedades inflamatorias, como por ejemplo la artritis reumatoide, la osteoartritis, el asma, la rinitis alérgica, la enfermedad pulmonar obstructiva crónica (EPOC), la psoriasis y la enfermedad inflamatoria de los intestinos.
CU2012000021A 2009-07-31 2010-07-29 Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos CU24103B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0913342.2A GB0913342D0 (en) 2009-07-31 2009-07-31 Compounds - 801
PCT/GB2010/051242 WO2011012896A2 (en) 2009-07-31 2010-07-29 Compounds - 801

Publications (2)

Publication Number Publication Date
CU20120021A7 CU20120021A7 (es) 2012-06-21
CU24103B1 true CU24103B1 (es) 2015-07-30

Family

ID=41129405

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000021A CU24103B1 (es) 2009-07-31 2010-07-29 Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos

Country Status (34)

Country Link
US (2) US8455483B2 (es)
EP (1) EP2459572B1 (es)
JP (1) JP5612092B2 (es)
KR (1) KR101664525B1 (es)
CN (1) CN102625808B (es)
AR (1) AR080601A1 (es)
AU (1) AU2010277384B2 (es)
BR (1) BR112012008043A2 (es)
CA (1) CA2768527C (es)
CL (1) CL2012000263A1 (es)
CO (1) CO6491034A2 (es)
CR (1) CR20120054A (es)
CU (1) CU24103B1 (es)
DO (1) DOP2012000032A (es)
EA (1) EA020566B1 (es)
ES (1) ES2702467T3 (es)
GB (1) GB0913342D0 (es)
GT (1) GT201200028A (es)
HK (1) HK1171755A1 (es)
HN (1) HN2012000217A (es)
IL (1) IL217557A (es)
MX (1) MX2012001232A (es)
MY (1) MY163117A (es)
NI (1) NI201200018A (es)
NZ (1) NZ597589A (es)
PE (1) PE20121441A1 (es)
SA (1) SA110310628B1 (es)
SG (1) SG177634A1 (es)
TR (1) TR201819140T4 (es)
TW (1) TWI443103B (es)
UA (1) UA106887C2 (es)
UY (1) UY32814A (es)
WO (1) WO2011012896A2 (es)
ZA (1) ZA201201473B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2394547T3 (es) 2008-02-06 2013-02-01 Astrazeneca Ab Compuestos
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
GB201021979D0 (en) * 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) * 2010-12-23 2011-02-02 Astrazeneca Ab Compound
US10435375B2 (en) 2015-05-05 2019-10-08 Northwestern University CXCR4 chemokine receptor modulators
CN109195975B (zh) * 2016-09-30 2022-01-04 四川海思科制药有限公司 一种二氮杂螺[5.5]十一碳烷衍生物及其用途
US11447485B2 (en) 2016-12-14 2022-09-20 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quanternary ammonium salt structure
PL3630752T3 (pl) 2017-06-01 2021-11-02 Bristol-Myers Squibb Company Podstawione związki zawierające azot
EP3682906A1 (en) * 2019-01-17 2020-07-22 Julius-Maximilians-Universität Würzburg Compound targeting norepinephrine transporter

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2707186A (en) 1954-05-06 1955-04-26 Hoffmann La Roche Imidazolone derivatives
AU565621B2 (en) 1983-04-26 1987-09-24 Smithkline Beckman Corporation Dopaminergic carbostyrils
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
GB9604578D0 (en) 1996-03-04 1996-05-01 Sericol Ltd Photocurable compositions
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
JO2537B1 (en) 2004-03-10 2010-09-05 جانسين فارماسوتيكا ان. في Aryl-pyridine or pyrezinate compounds replaced with heterogeneous pentagonal rings used as inhibitors of MTB proteins
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
US20050215542A1 (en) 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
AU2005293384A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as B Raf inhibitors
WO2006051373A1 (en) 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
PT1961744E (pt) * 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
WO2008021375A2 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
AU2007336074B2 (en) 2006-12-20 2011-09-22 Astrazeneca Ab Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases
GB0702413D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
ES2394547T3 (es) * 2008-02-06 2013-02-01 Astrazeneca Ab Compuestos
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801

Also Published As

Publication number Publication date
SA110310628B1 (ar) 2014-02-27
CA2768527A1 (en) 2011-02-03
US8455483B2 (en) 2013-06-04
WO2011012896A3 (en) 2011-04-21
PE20121441A1 (es) 2012-11-16
DOP2012000032A (es) 2017-08-15
EP2459572B1 (en) 2018-09-12
CN102625808A (zh) 2012-08-01
KR101664525B1 (ko) 2016-10-11
TW201107335A (en) 2011-03-01
CL2012000263A1 (es) 2012-08-31
AR080601A1 (es) 2012-04-25
WO2011012896A2 (en) 2011-02-03
CN102625808B (zh) 2014-08-27
US20110053909A1 (en) 2011-03-03
CA2768527C (en) 2017-07-11
CO6491034A2 (es) 2012-07-31
SG177634A1 (en) 2012-02-28
IL217557A0 (en) 2012-02-29
US8476265B2 (en) 2013-07-02
JP2013500958A (ja) 2013-01-10
JP5612092B2 (ja) 2014-10-22
CR20120054A (es) 2012-03-26
TR201819140T4 (tr) 2019-01-21
AU2010277384B2 (en) 2014-01-30
UA106887C2 (uk) 2014-10-27
GB0913342D0 (en) 2009-09-16
GT201200028A (es) 2013-09-26
US20130018037A1 (en) 2013-01-17
NI201200018A (es) 2012-09-10
AU2010277384A1 (en) 2012-03-22
ZA201201473B (en) 2012-11-28
TWI443103B (zh) 2014-07-01
EA020566B1 (ru) 2014-12-30
BR112012008043A2 (pt) 2020-08-25
IL217557A (en) 2015-01-29
MY163117A (en) 2017-08-15
MX2012001232A (es) 2012-03-26
EA201290077A1 (ru) 2012-08-30
UY32814A (es) 2011-02-28
NZ597589A (en) 2013-12-20
CU20120021A7 (es) 2012-06-21
EP2459572A2 (en) 2012-06-06
HK1171755A1 (en) 2013-04-05
ES2702467T3 (es) 2019-03-01
KR20120056838A (ko) 2012-06-04
HN2012000217A (es) 2015-03-09

Similar Documents

Publication Publication Date Title
CU24103B1 (es) Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos
CY1122639T1 (el) Παραγωγα 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου ως ενδιαμεσα στην παρασκευη παραγωγων [(5-αλογονοφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)- αμινο]αλκανοϊκου οξεος
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY2020032I1 (el) Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια
CY1121318T1 (el) Συμπλοκα λιποπρωτεϊνων και παρασκευη και χρησεις αυτων
CY1118610T1 (el) Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου
CY1116791T1 (el) 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης
GT200900289A (es) Compuestos organicos.-
SMT201300043B (it) Inibitori del virus dell'epatite c
ECSP11010857A (es) Nuevas benzamidas, su preparación y su uso como medicamentos
CR20140238A (es) Derivados nucleósidos con sustitución 2´, 4´- difluoro-2´-metilo como inhibidores de la replicación del arn del vhc
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
EA201290296A1 (ru) Циклические пептиды, специфичные к рецептору меланокортина-1
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
CO6801794A2 (es) Derivados de isoxazolina en el tratamiento de ectoparasitos y su proceso de producción
ECSP13012862A (es) Terapéuticos a base de levadura para infección de la hepatitis b crónica
CR20140301A (es) Derivados de betulina
WO2012143796A3 (en) Anti-inflammation compounds
CL2013003512A1 (es) Compuestos derivados de 7-(heterociclilo, arilo o heteroarilo) de piridopirazinas o sus sales; composicion farmaceutica que los comprende, utiles para el tratamiento de una enfermedad mediada por ptk quinasa tales como asma alergica, rinitis alergica, artritis reumatoide, esclerosis multiple, lupus, leucopenia, entre otras enfermedades.
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
ECSP16079730A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
CY1121115T1 (el) Σικλεσονιδη για τη θεραπεια της νοσου των αεραγωγων σε αλογα
EA201391173A1 (ru) Изоксазолидиновые производные

Legal Events

Date Code Title Description
FG Grant of patent